Lunit Inc. (328130.KQ)
KOSDAQ · KRW · Healthcare · Health Information Services
₩14,460 (-1.57%) as of
Key statistics
- Market cap
- 1.08T
- Forward P/E
- -14.71
- Dividend yield
- 0.00%
- 52-week range
- 8,180.00 – 24,550.00
- Beta
- 1.20
- Revenue (TTM)
- 91.82B
- Profit margin
- -60.65%
- Analyst target
- ₩9,000
- Volume
- 4.76M
About Lunit Inc.
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research; and with Summit Therapeutics Inc. to apply AI-powered SCOPE IO pathology platform for tumor microenvironment analysis in immuno-oncology development. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- Seoul, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.